Last reviewed · How we verify
TY-1091
At a glance
| Generic name | TY-1091 |
|---|---|
| Sponsor | TYK Medicines, Inc |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- A Study of TY-1091 in Patients With Advanced Solid Tumors (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- TY-1091 CI brief — competitive landscape report
- TY-1091 updates RSS · CI watch RSS
- TYK Medicines, Inc portfolio CI